Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India

Author: Novartis, Published on: 1 April 2013

A decision issued today by the Indian Supreme Court regarding the Novartis breakthrough medicine Glivec® (imatinib mesylate) provides clarification on Indian patent law and discourages innovative drug discovery essential to advancing medical science for patients...

Read the full post here

Related companies: Novartis